Valuation: Alkermes plc

Market Cap 7.28B 6.35B 5.98B 5.44B 10.21B 697B 10.22B 71.59B 27.59B 355B 27.34B 26.74B 1,146B P/E 2026 *
-85.1x
P/E 2027 * 59.7x
Enterprise Value 8.02B 7B 6.59B 6B 11.25B 769B 11.26B 78.9B 30.41B 392B 30.14B 29.47B 1,263B EV / Sales 2026 *
4.4x
EV / Sales 2027 * 4.09x
Free-Float
89.45%
Yield 2026 *
-
Yield 2027 * -
1 day+1.29%
1 week-3.45%
Current month-5.83%
1 month-8.44%
3 months-3.85%
6 months+59.69%
Current year+58.15%
1 week 43.11
Extreme 43.11
47.4
1 month 43.11
Extreme 43.11
49.58
Current year 27
Extreme 27
55.67
1 year 26.99
Extreme 26.99
55.67
3 years 22.01
Extreme 22.01
55.67
5 years 21.24
Extreme 21.24
55.67
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 53 31/07/2026
Director of Finance/CFO 53 14/09/2025
Chief Tech/Sci/R&D Officer 58 29/05/2017
Director TitleAgeSince
Chairman 64 31/08/2011
Director/Board Member 53 31/07/2026
Director/Board Member 74 25/05/2016
Date Insider Type Main position Quantity % Market Cap. Importance
03/09/26 Sell

Compliance Officer

-2,034 0.0012%
01/09/26 Exercice

Chief Technology Officer

19,000 0.0113%
17/08/26 Sell

Executive/Senior Manager

-7,576 0.0045%
Change 5-day change 1-year change 3-year change Capi.($)
+1.33%-3.45%+60.15%+48.94% 7.28B
+0.59%+2.73%+1.48%+28.74% 46.28B
+0.56%+0.84%+42.62%+34.50% 43.85B
+0.74%-5.85%+334.82%+533.55% 40.93B
+4.15%+3.41%+8.31%+94.85% 39.89B
+1.11%+1.80%+11.52%+43.15% 29.5B
+1.72%+4.55%+24.98%+158.50% 17.09B
+0.91%-9.56% - - 15.55B
+2.12%+8.18%+24.54%+41.21% 15.22B
+0.84%+26.14%-8.62% - 14.05B
Average +1.43%+3.01%+55.53%+122.93% 26.96B
Weighted average by Cap. +1.45%+1.88%+68.60%+139.26%

Financials

2026 *2027 *
Net sales 1.82B 1.59B 1.5B 1.36B 2.56B 175B 2.56B 17.95B 6.92B 89.06B 6.85B 6.7B 287B 1.94B 1.7B 1.6B 1.45B 2.73B 186B 2.73B 19.13B 7.37B 94.91B 7.31B 7.14B 306B
Net income -89.92M -78.4M -73.84M -67.25M -126M -8.61B -126M -884M -341M -4.39B -338M -330M -14.16B 119M 104M 98.01M 89.26M 167M 11.43B 168M 1.17B 452M 5.82B 448M 438M 18.8B
Net Debt 744M 649M 611M 556M 1.04B 71.27B 1.04B 7.32B 2.82B 36.3B 2.79B 2.73B 117B 670M 584M 550M 501M 939M 64.18B 941M 6.59B 2.54B 32.69B 2.52B 2.46B 105B
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
21/09/26 US$44.23 +1.94% 1,484,510
18/09/26 US$43.39 -7.11% 6,935,802
17/09/26 US$46.71 +1.39% 1,423,622
16/09/26 US$46.07 +0.09% 1,854,651
15/09/26 US$46.03 +0.44% 2,151,164
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
43.39USD
Average target price
56.35USD
Spread / Average Target
+29.88%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALKS Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!